Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! Get more Watchlists, Portfolios, Custom Views and Chart Templates with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Nanobiotix S.A. ADR (NBTX)

Nanobiotix S.A. ADR (NBTX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 1,034,813
  • Shares Outstanding, K 48,401
  • Annual Sales, $ -7,780 K
  • Annual Income, $ -73,730 K
  • EBIT $ 0 M
  • EBITDA $ -72 M
  • 60-Month Beta 0.70
  • Price/Sales 121.42
  • Price/Cash Flow N/A
  • Price/Book N/A

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 6 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/25
See More
  • Average Estimate N/A
  • Number of Estimates 0
  • High Estimate N/A
  • Low Estimate N/A
  • Prior Year N/A
  • Growth Rate Est. (year over year) unch

Price Performance

See More
Period Period Low Period High Performance
1-Month
19.61 +6.97%
on 01/12/26
24.01 -12.64%
on 12/22/25
-1.72 (-7.59%)
since 12/12/25
3-Month
14.78 +41.92%
on 10/27/25
28.51 -26.43%
on 10/16/25
-7.25 (-25.70%)
since 10/14/25
52-Week
2.92 +618.36%
on 01/15/25
30.35 -30.89%
on 10/13/25
+18.11 (+630.88%)
since 01/14/25

Most Recent Stories

More News
Nanobiotix Updates Voting Rights and Share Capital Details

Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. Nanobiotix...

NBTX : 20.97 (-1.90%)
This Stock Is Up 440% in a Year. Is It an Undiscovered Star or a Flash in the Pan?

Nanobiotix (NBTX) is a clinical-stage nanomedicine company showing exceptional price momentum and technical strength. Shares are trading at new all-time highs. NBTX has surged 440% over the past year....

NBTX : 20.97 (-1.90%)
Stifel Nicolaus Remains a Buy on Nanobiotix (0QAV)

Stifel Nicolaus analyst Clémence Thiers maintained a Buy rating on Nanobiotix today and set a price target of €25.00. The company’s shares opened today at €18.10.Elevate Your Investing Strategy:...

NBTX : 20.97 (-1.90%)
Jefferies Reaffirms Their Buy Rating on Nanobiotix (0QAV)

Jefferies analyst Lucy Codrington maintained a Buy rating on Nanobiotix today and set a price target of €21.00. The company’s shares opened today at €17.06.Elevate Your Investing Strategy: Take advantage...

NBTX : 20.97 (-1.90%)
Nanobiotix SA ADR Reports Revenue Surge Amid Strategic Advances

Nanobiotix Sa ADR ( (NBTX) ) has released its Q2 earnings. Here is a breakdown of the information Nanobiotix Sa ADR presented to its investors.Elevate Your Investing Strategy: Take advantage of TipRanks...

NBTX : 20.97 (-1.90%)
Nanobiotix Reports Promising Phase 1 Results for Esophageal Cancer Treatment

Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. Nanobiotix...

NBTX : 20.97 (-1.90%)
Nanobiotix: Voting Rights and Shares Capital of the Company

Regulatory News:

NANO : 35.33 (-0.81%)
NBTX : 20.97 (-1.90%)
Nanobiotix Provides Business Update and Reports Financial Results for the First Half of 2022

Regulatory News:

NBTX : 20.97 (-1.90%)
Nanobiotix to Announce Half Year 2022 Financial Results on September 28, 2022

Regulatory News:

NBTX : 20.97 (-1.90%)
Nanobiotix Establishes Recommended Dose for Planned Registrational Study Evaluating NBTXR3 Plus Anti-PD-1 for Patients With Metastatic Head and Neck Cancer Resistant to Prior Immunotherapy

Regulatory News:

NBTX : 20.97 (-1.90%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 56% Buy with a Weakening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

NANOBIOTIX is a late-stage clinical biotechnology company pioneering physics-based approaches to expand treatment possibilities for patients with cancer and other major diseases. NANOBIOTIX is based in CAMBRIDGE, Mass.

See More

Key Turning Points

3rd Resistance Point 23.10
2nd Resistance Point 22.27
1st Resistance Point 21.83
Last Price 20.97
1st Support Level 20.56
2nd Support Level 19.73
3rd Support Level 19.29

See More

52-Week High 30.35
Last Price 20.97
Fibonacci 61.8% 19.87
Fibonacci 50% 16.64
Fibonacci 38.2% 13.40
52-Week Low 2.92

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar